Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen's $1.6B Bid for Digene Passes Federal Waiting Period

NEW YORK (GenomeWeb News) — Qiagen today said that federal regulators have cleared its planned acquisition of Digene.
 
The company said the Hart-Scott-Rodino antitrust deadline passed on midnight yesterday without a hitch, enabling the shop to buy Digene for $1.6 billion.
 
The deal is subject to the tender of a majority of Digene's common stock on a fully diluted basis before 11:59 p.m. EST on July 20, unless the offer is extended, as well as approval by Qiagen’s shareholders, among other conditions.
 
Qiagen said it expects to close the acquisition in August or September.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.